Eighty-eight patients with obesity with mild cognitive impairment（MCI） from the Multicenter Nutrition and Chronic Disease Cohort, who met the inclusion and exclusion criteria, were selected as study subjects and randomly divided into 2 groups, i.e., the placebo group and the n-3 PUFA intervention group. Subjects in the intervention group were given supplemental n-3 PUFA (supplied in 1.36 g fish oil capsules); the placebo group took placebo (1.36 g/d), and the intervention period was 12 consecutive months. General information, dietary intake, body composition, exercise, overall cognitive function and multidimensional cognitive function, abundance of Mycobacterium avium and its metabolites acetic acid and propionic acid content, beige adiposity markers, inflammation-related factors, and lipid metabolism were collected at baseline, at the end of 6 months and at the end of 12 months of the intervention, respectively, and the adherence of the two groups of subjects was also assessed. To analyze the effects of n-3 PUFA intervention on cognitive function in patients with obesity with MCI and to explore the possible mechanisms.
Age range
35 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Height, Waist
Timeframe: Baseline, 6 months, 12 months
weight
Timeframe: Baseline, 6 months, 12 months
Total Body Water
Timeframe: Baseline, 6 months, 12 months
body protein, inorganic salts, and body fat
Timeframe: Baseline, 6 months, 12 months
Appendicular skeletal muscle mass index
Timeframe: Baseline, 6 months, 12 months
Cognitive function assessment
Timeframe: Baseline, 6 months, 12 months
Dietary composition
Timeframe: Baseline
Dietary Inflammation Index
Timeframe: Baseline
Species and abundance of intestinal flora
Timeframe: Baseline, 6 months, 12 months
Metabolite levels of intestinal flora
Timeframe: Baseline, 6 months, 12 months
Plasma inflammatory factor levels
Timeframe: Baseline, 6 months, 12 months
Erythrocyte Membrane n-3 PUFA Levels
Timeframe: Baseline, 6 months, 12 months
Plasma Beige Lipid Marker Levels
Timeframe: Baseline, 6 months, 12 months
Fecal Akkermansia abundance
Timeframe: Baseline, 6 months, 12 months
Fecal Amuc_1100 expression levels
Timeframe: Baseline, 6 months, 12 months
Detection of signaling pathway related indicators of plasma fat metabolism
Timeframe: Baseline, 6 months, 12 months
Levels of lipopolysaccharide
Timeframe: Baseline, 6 months, 12 months
Plasma lipid oxide concentrations
Timeframe: Baseline, 6 months, 12 months
Levels of fatty acid synthetase
Timeframe: Baseline, 6 months, 12 months